[CAS NO. 1883650-96-1] CDDO-2P-Im
PRODUCTS SPECIFICATIONS [1883650-96-1]
DESCRIPTION [1883650-96-1]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 618.81 |
| Molecular Formula | C39H46N4O3 |
| SMILES | CC(C)([C@](CC[C@@]([C@@]1(CC[C@]2(CCC(C)(C[C@]2([C@]13[H])[H])C)C(N4C=C(C5=NC=CC=C5)N=C4)=O)C)6C)7[H])C(C(C#N)=C[C@]7(C)C6=CC3=O)=O |
Summary
In Vitro
CDDO-2P-Im (100 nM; 4 days) induces differentiation of U937 cells at 100 nM
[1]
.
CDDO-2P-Im suppresses NO production in RAW264.7 cells with an IC
50
of 5.8 nM
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Apoptosis Analysis [1]
| Cell Line: | U937 cells |
| Concentration: | 30 nM, 100 nM |
| Incubation Time: | 4 days |
| Result: | Induced differentiation of U937 cells at 100 nM. |
In Vivo
CDDO-2P-Im is more stable than CDDO-Im in pharmacokinetic studies
[1]
.
CDDO-2P-Im significantly elevates heme oxygenase-1 (HO-1) and quinone reductase (NQO1) mRNA and protein levels in various mouse tissues in vivo
[1]
.
CDDO-2P-Im (50-200 mg/kg; diet; for 16 weeks) decreases the number, the size and the severity of tumors in A/J mice
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Seven week-old female A/J mice [1] |
| Dosage: | 50 mg/kg, 200 mg/kg |
| Administration: | Diet; for 16 weeks |
| Result: | Decreased the number, the size and the severity of tumors. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 125 mg/mL ( 202.00 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.6160 mL | 8.0800 mL | 16.1600 mL |
| 5 mM | 0.3232 mL | 1.6160 mL | 3.2320 mL |
| 10 mM | 0.1616 mL | 0.8080 mL | 1.6160 mL |
-
1.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (3.36 mM); Clear solution